BR9606409A - Composto opticamente ativo composição farmacêutica processos para inibir agregação de plaqueta em um animal de sangue quente ligação de fibrinogênio a gpiib/iia em um animal de sangue quente e eventos trombóticos que acompanham agnina instável em animal de sangue quente e uso do composto opticamante ativo - Google Patents

Composto opticamente ativo composição farmacêutica processos para inibir agregação de plaqueta em um animal de sangue quente ligação de fibrinogênio a gpiib/iia em um animal de sangue quente e eventos trombóticos que acompanham agnina instável em animal de sangue quente e uso do composto opticamante ativo

Info

Publication number
BR9606409A
BR9606409A BR9606409A BR9606409A BR9606409A BR 9606409 A BR9606409 A BR 9606409A BR 9606409 A BR9606409 A BR 9606409A BR 9606409 A BR9606409 A BR 9606409A BR 9606409 A BR9606409 A BR 9606409A
Authority
BR
Brazil
Prior art keywords
warm
active compound
optically active
blooded animal
blooded
Prior art date
Application number
BR9606409A
Other languages
English (en)
Portuguese (pt)
Inventor
Stuart Dennett Mills
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/457,538 external-priority patent/US5652242A/en
Priority claimed from GBGB9518188.9A external-priority patent/GB9518188D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of BR9606409A publication Critical patent/BR9606409A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9606409A 1995-06-01 1996-05-28 Composto opticamente ativo composição farmacêutica processos para inibir agregação de plaqueta em um animal de sangue quente ligação de fibrinogênio a gpiib/iia em um animal de sangue quente e eventos trombóticos que acompanham agnina instável em animal de sangue quente e uso do composto opticamante ativo BR9606409A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/457,538 US5652242A (en) 1993-03-29 1995-06-01 Heterocyclic derivatives
GBGB9518188.9A GB9518188D0 (en) 1995-09-07 1995-09-07 Optically active derivative
PCT/GB1996/001260 WO1996038416A1 (en) 1995-06-01 1996-05-28 (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)piperazin-1-yl]phenoxy} butyric acid as cellular adhesion inhibitor

Publications (1)

Publication Number Publication Date
BR9606409A true BR9606409A (pt) 1997-09-30

Family

ID=26307696

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9606409A BR9606409A (pt) 1995-06-01 1996-05-28 Composto opticamente ativo composição farmacêutica processos para inibir agregação de plaqueta em um animal de sangue quente ligação de fibrinogênio a gpiib/iia em um animal de sangue quente e eventos trombóticos que acompanham agnina instável em animal de sangue quente e uso do composto opticamante ativo

Country Status (31)

Country Link
EP (1) EP0796247A1 (de)
JP (1) JP2885941B2 (de)
KR (1) KR100245957B1 (de)
AT (1) AT406675B (de)
AU (1) AU710105B2 (de)
BE (1) BE1009520A5 (de)
BR (1) BR9606409A (de)
CA (1) CA2194397A1 (de)
CH (1) CH691808A5 (de)
CZ (1) CZ26997A3 (de)
DE (1) DE19680509T1 (de)
DK (1) DK10697A (de)
ES (1) ES2137886B1 (de)
FI (1) FI970393A0 (de)
GB (1) GB2304340B (de)
GR (1) GR1002702B (de)
HU (1) HUP9700274A3 (de)
IE (1) IE960405A1 (de)
IL (1) IL118477A0 (de)
IT (1) IT1290839B1 (de)
LU (1) LU90008B1 (de)
MC (1) MC2418A1 (de)
MX (1) MX9700379A (de)
NL (1) NL1003243C2 (de)
NO (1) NO307460B1 (de)
NZ (1) NZ308597A (de)
PL (1) PL318440A1 (de)
SE (1) SE510812C2 (de)
SK (1) SK13097A3 (de)
TR (1) TR199700020T1 (de)
WO (1) WO1996038416A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0100158A3 (de) * 1982-07-28 1985-03-27 The Upjohn Company (3-Pyridinyl)-heteroalkarylalkanole, ihre Alkansäuren und ihre Ester
GB8609630D0 (en) * 1986-04-19 1986-05-21 Pfizer Ltd Anti-arrhythmia agents
AU692438B2 (en) * 1993-03-29 1998-06-11 Astrazeneca Ab Heterocyclic derivatives as platelet aggregation inhibitors
EP0690847A1 (de) * 1993-03-29 1996-01-10 Zeneca Limited Heterozyklische derivate als plätchenaggregationsinhibitoren

Also Published As

Publication number Publication date
NO970437D0 (no) 1997-01-31
HUP9700274A2 (hu) 1999-06-28
JP2885941B2 (ja) 1999-04-26
FI970393L (fi) 1997-01-30
SE9700203L (sv) 1997-01-24
IL118477A0 (en) 1996-09-12
ITMI961113A0 (it) 1996-05-31
NL1003243C2 (nl) 1996-12-04
NZ308597A (en) 1998-11-25
JPH09512836A (ja) 1997-12-22
AT406675B (de) 2000-07-25
EP0796247A1 (de) 1997-09-24
CH691808A5 (de) 2001-10-31
TR199700020T1 (tr) 1997-04-22
MC2418A1 (fr) 1997-05-23
GB2304340A (en) 1997-03-19
GB9627127D0 (en) 1997-02-19
ES2137886B1 (es) 2000-08-16
ES2137886A1 (es) 1999-12-16
HU9700274D0 (en) 1997-04-28
CZ26997A3 (en) 1997-08-13
SE9700203D0 (sv) 1997-01-24
SE510812C2 (sv) 1999-06-28
BE1009520A5 (fr) 1997-04-01
NO307460B1 (no) 2000-04-10
GR1002702B (el) 1997-05-22
MX9700379A (es) 1997-04-30
FI970393A7 (fi) 1997-01-30
IT1290839B1 (it) 1998-12-14
ITMI961113A1 (it) 1997-12-01
AU5827296A (en) 1996-12-18
FI970393A0 (fi) 1997-01-30
LU90008B1 (fr) 1997-04-16
KR100245957B1 (ko) 2000-04-01
IE960405A1 (en) 1996-12-11
ATA900596A (de) 1999-12-15
DK10697A (da) 1997-04-01
GB2304340B (en) 1998-07-29
SK13097A3 (en) 1997-08-06
KR970704689A (ko) 1997-09-06
CA2194397A1 (en) 1996-12-05
DE19680509T1 (de) 1997-12-04
NO970437L (no) 1997-02-20
PL318440A1 (en) 1997-06-09
AU710105B2 (en) 1999-09-16
HUP9700274A3 (en) 2000-02-28
WO1996038416A1 (en) 1996-12-05

Similar Documents

Publication Publication Date Title
DE69813922D1 (de) Hydroxycarbonsäure oder Retinoid enthaltende Zusammensetzungen
FI954963A7 (fi) Poly-1-n-alkeeniamiineja ja näitä sisältäviä poltto- ja voiteluainekoo stumuksia
FI855117L (fi) Segmenttipolyestereitä ja niiden kaltaisia yhdisteitä käytettäviksi lianirrotusaineina pesuainekoostumuksissa
BR9508948A (pt) Agulha para uso na distribuição sem vareta de prendedores plásticos
KR950704251A (ko) 프롤릴 엔도펩티다아제 억제 활성을 갖는 화합물 및 그 약학적 용도(compound with prolyl endopeptdase inhibitor activity and pharmaceutical use thereof)
BR9611377A (pt) Inibidor de trombina de ligação não lenta processo para preparar o mesmo composição farmacêutica e uso do inibidor de trombina
CY2010015I1 (el) Φθοροαλκοξυ-υποκατεστημενα βεναμιδια και η χρησιμοποιηση τους σαν κυκλικοι-νουκλεοτιδικοι αναστολεις φωσφοδιεστερασης
FI20041415L (fi) Booriesteri- ja -happoyhdisteet sekä näiden synteesi ja käyttö
FI971412A7 (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasie n estäjinä
MX173582B (es) Espesante de arcilla para emplear en sistemas basados en agua y compuestos de union que contienen esas composiciones
ID967B (id) Proses dan alat untuk membuat asam tereftalat
BR9307158A (pt) Mancal tendo almofadas separadas e metodos para fazer o mesmo
ES2148593T3 (es) Compuestos retinoides trienoicos novedosos y metodos.
BR9811458A (pt) "sistema solvente para penetração melhorada de compostos farmacêuticos"
ID26492A (id) Campuran senyawa iodopropargil dan donor formaldehid
DE69520056D1 (de) Verbindungen zur Hemmung von Thrombin
BR9402060A (pt) Composição de graxa de uréia
FI951992A7 (fi) Uusia substituoituja atsetidinoneja anti-inflammatorisina ja antidegeneratiivisina aineina
FI20001777A7 (fi) Substituoidun triatsolin sulfaattisuola ja sen farmaseuttisia koostumuksia
DE69307830D1 (de) Insektizide Zusammensetzung
BR9606409A (pt) Composto opticamente ativo composição farmacêutica processos para inibir agregação de plaqueta em um animal de sangue quente ligação de fibrinogênio a gpiib/iia em um animal de sangue quente e eventos trombóticos que acompanham agnina instável em animal de sangue quente e uso do composto opticamante ativo
FI961716A7 (fi) Ibuprofeeni ja flurbiprofeeni kutinaa lievittävinä aineina
GT199700054A (es) Pesticidas que contienen alcaloides de benzofenantridina
BR9608766A (pt) Composição lubrificante e concentrado de aditivo para preparar a composição lubrificante
EP0867168A3 (de) Topische Zubereitungen mit oxidationsempfindlichen Wirkstoffen

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal